Subscribe To
MEDP / Here is Why Growth Investors Should Buy Medpace (MEDP) Now
MEDP News
By Zacks Investment Research
November 1, 2023
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year. more_horizontal
By Zacks Investment Research
October 26, 2023
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes. more_horizontal
By Zacks Investment Research
October 26, 2023
Medpace (MEDP) Upgraded to Buy: Here's What You Should Know
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal
By Zacks Investment Research
October 23, 2023
Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates
Medpace (MEDP) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings more_horizontal
By Zacks Investment Research
October 13, 2023
Are Medical Stocks Lagging Medpace (MEDP) This Year?
Here is how Medpace (MEDP) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. more_horizontal
By Zacks Investment Research
September 25, 2023
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials. more_horizontal
By Seeking Alpha
September 9, 2023
Medpace: A Great Anchor For A Long-Term Portfolio
Medpace is a Contract Research Organization (CRO) that provides outsourced clinical development services to the biotech, pharma, and medical device in more_horizontal
By Zacks Investment Research
September 8, 2023
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials. more_horizontal